Member Info for baz9707

More coming on so expect some liquidity, added some more on the drop.

Clifford Press, chief executive of California-based Acacia, described the criticism as “silly”.

“There was one single price given, which we agreed for the entire portfolio,” he said. “The allocation for individual positions is a function of the tax and accounting treatment in a multi-jurisdictional trade,” he said.

Press said most of the sales had been of American companies — including Evofem Biosciences and Theravance Biopharma — and that he planned to manage the remaining investments, which include “unicorns” Oxford Nanopore and Immunocore, from a new headquarters in Oxford.

Would be great to see them get listed on an exchange.
20m contracts would pave the way.
https://twitter.com/Bazreynolds9707/status/1274739159803068418?s=19

Let's see profit booked and office in Oxford to manage the PF.
https://twitter.com/Bazreynolds9707/status/1274746315331813376?s=19

If my theory is correct should have 2 maybe 3 holding RNS.
This will go on a run once all this fund debacle is sorted, I think Lawson will have had some correspondance with them.

Now the wait to see how many and at what price the big sell order is at. JBER seem to have took the shares 6p seems to be the price.

Catching up looks a very odd day must have been a large sell, same happened when it went up 600% in a few days let's hope. .

The main part of this statement is cash to last to end of 2021.
PF companies require no further funding.
Sit back and reap the rewards.

Cash on the balance sheet as at 31 December 2019 was £3.5 million (2018: £2.9 million). Cash used in operations in 2019, was £4.1 million (2018: £8.3 million). Group companies are not expected to require any further funding hereafter in 2020. ProAxsis required a short loan in January 2020 which has now been repaid. £1.2m is held in the Company, giving it and the Group enough cash to operate until the end of 2021. The cash held within subsidiary Glycotest, Inc., of £2.2m (2018: £0.1m) is not freely available for use within the wider group as it would need the consent of a 40% minority shareholder.

Officially a Covid vaccine play
NetScientific RNS to follow
https://twitter.com/Bazreynolds9707/status/1273238157652344838?s=19

Delivering another mark up on an investment and in only 2 weeks, have a look at the people running it plenty of contacts and knowledge.
PIRI will tap into that for a direct investment which should be a decent catalyst for the share price.

I am expecting a payout at some stage from the sale of Glycotest or ProAxsis.
This is where the shareholder value will come.
ProAxsis has proved its concept has a strong sales pipeline and will be profit making now. It is more appeal than most AIM companies.
Glycotest 10m funding values it at 20m before the royalties from fosun, it is carrying out 4 more trials in the US now and will launch HCC Q3.
PDSB has 3 stage 2 trials 1 under way and 2 very soon. Covid vaccine news on its way, buyout or merger possible.
All in NetScientific is funded for another year 3.5m cash in PF companies and 700k loan that it can draw on.
Mkt cap 4m cheap.

Will prove to be cheap at this level, hoping for some decent news from PF companies they hold 50% in.

Small Clip of the PDSB presentation today. In talks for non dilutive government funding for Covid Vaccine.
https://twitter.com/Bazreynolds9707/status/1270446187993333764?s=19

Odd goings on here being held down for some reason.

Looking at lv2 I do think it is now primed for a run.

6p wonder how many you can buy first thing, I would bet not alot.

Same bud
You can track most of the sells, this will just make the jump in SP higher.
Mms proper messed this up, I just made the spread closer and more realistic SP would be less volatile and attract investors.

Should get A copy of the RNS on here this morning hopefully set the tone for a decent day.

https://twitter.com/Bazreynolds9707/status/1268643074827223042?s=19

6.9p - 7.8p real spread
No worries as won't matter when this is let loose.

Annoying when it's NT to buy and sells are at at mid, surely they can sort the spread out.